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1Department of Emergency and Disaster Medicine, 2Infection Control Team, Juntendo University Urayasu
Hospital, Urayasu, 3Department of Emergency and Critical Care Medicine, University of Tsukuba Hospital,
Tsukuba, 4Department of Respiratory Medicine, and 5Department of Clinical Pathology, Juntendo University
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Aim: Acinetobacter baumannii is commonly associated with outbreaks and antibiotic-resistant nosocomial infection. This study
aimed to determine the relationship between antibiotic resistance and genotypes of A. baumannii.
Methods: A study was undertaken in the critical care center (CCC) of Juntendo University Urayasu Hospital (Urayasu, Japan)
between January 2012 and September 2015. Antimicrobial susceptibility tests were carried out according to the Clinical and Labora-
tory Standards Institute guidelines. All A. baumannii isolates were verified to carry carbapenemase genes and the ISAba1 element
using polymerase chain reaction. The genetic relationship of all A. baumannii isolates was determined by pulsed-field gel elec-
trophoresis and multilocus sequence typing.
Results: During the study period, 1634 patients were admitted to the CCC. Acinetobacter baumannii was detected in 43 patients
(average age, 58  19 years; 67.4% men). Six patients were determined to be extensively drug-resistant A. baumannii and 21
patients determined to be multidrug-resistant A. baumannii. Antimicrobial susceptibility linked genotypes of A. baumannii. Molecular
characterization by pulsed-field gel electrophoresis and multilocus sequence typing showed that closely related clones of A. bauman-
nii had spread in the CCC.
Conclusion: Resistance to antimicrobial drugs was significantly associated with certain A. baumannii genotypic types and molecu-
lar types. Thus, we might be able to predict whether the genotype has spread in the CCC or not when the susceptibility is examined,
facilitating the appropriate isolation of patients.
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INTRODUCTION
ACINETOBACTER BAUMANNII is an aerobic Gram-negative bacillus that is ubiquitous in the natural envi-
ronment. Although A. baumannii is typically harmless and
colonizes the skin and respiratory tracts of patients, as well
as medical instruments,1 it is an opportunistic pathogen that
can cause bacteremia, ventilator-associated pneumonia, and
urinary tract infection in the hospital setting.2 Since the early
1980s, it has been associated with antibiotic-resistant noso-
comial infections, especially in intensive care units in Eur-
ope.
The intercontinental spread of multidrug-resistant A. bau-
mannii (MDR-AB) between Europe and other continents
has been described since the 1990s.2 Molecular epidemio-
logical typing has been used to investigate intercontinental
outbreaks of A. baumannii and to determine the genotypes
of A. baumannii isolates from various locations worldwide,
mainly in Europe. In addition to clones identiﬁed from these
international outbreaks, two A. baumannii clones from Eur-
ope that have spread globally were identiﬁed. These have
been designated as global clone (GC) I and II (previously
known as the European clone or international clone I and
II). The GCI and II lineages were ﬁrst reported 23 years
ago.3
Corresponding: Kensuke Murata MD, PhD, Department of
Emergency and Disaster Medicine, Juntendo University Urayasu
Hospital, 2-1-1 Tomioka, Urayasu City, Chiba, Japan. E-mail
kensukeee@juntendo-urayasu.jp.
Received 25 Mar, 2019; accepted 28 Jun, 2019; online
publication 22 Jul, 2019
Funding information
This study was supported by a grant from the Ministry of Health,
Labor and Welfare of Japan [H27 Kiban Ippan 15H04795].
© 2019 The Authors. Acute Medicine & Surgery published by John Wiley & Sons Australia, Ltd on behalf of
Japanese Association for Acute Medicine
1 of 7
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited and
is not used for commercial purposes.
Acute Medicine & Surgery 2020;7:e445 doi: 10.1002/ams2.445
In 2008, a university hospital in Japan reported that 23
patients in the critical care center (CCC) were infected with
MDR-AB, and four patients died.4 Subsequently, several
CCCs in Japan also reported continuous MDR-AB out-
breaks in 2009, 2010, and 2011. Each CCC serves a prede-
termined population and accepts ambulances from the
surrounding area. Thus, a CCC closure due to an outbreak
can disrupt the local emergency care system. In 2010, four
academic associations related to infectious diseases in Japan
suggested the necessity of effective Acinetobacter surveil-
lance, promotion of the development of new antibiotics, and
their accelerated approval for domestic use (http://
www.kansensho.or.jp/modules/guidelines/index.php?con-
tent_xml:id=26).
Acinetobacter baumannii can easily acquire multidrug
resistance, including resistance to carbapenem.5 The most
common mechanism of carbapenem resistance in A. bau-
mannii is through the action of carbapenem-hydrolyzing
class D b-lactamase, also known as an oxacillinase
(OXA). To date, four main phylogenetic subgroups of
OXA-type carbapenemase (OTC) have been identiﬁed in
A. baumannii: OXA-23-like, OXA-40-like, OXA-51-like,
and OXA-58-like. The OXA-51-like enzymes are chro-
mosomally encoded naturally occurring OTCs in A. bau-
mannii. However, OXA-51-like enzymes are not typically
potent against antibiotics and were reported to confer car-
bapenem resistance when an ISAba1 element is inserted
upstream of the gene. Genes encoding acquired OXAs,
including OXA-23-like, OXA-40-like, and OXA-58-like,
have been found mostly on plasmids. An insertion
sequence linked to OXA-23 and OXA-58 genes were
also reported to regulate the expression of the carbapene-
mase.2
The expression of carbapenem-hydrolyzing class B b-lac-
tamases, also known as metallo-b-lactamases (MBLs), is a
powerful mechanism for carbapenem resistance carried by
plasmids. To date, three groups of acquired MBLs have
been identiﬁed in A. baumannii: IMP-like, VIM-like, and
SIM-1. However, MBL rarely mediates carbapenem resis-
tance in A. baumannii.6
The CCC at Juntendo University Urayasu Hospital
(Urayasu, Japan) has been experiencing an MDR-AB out-
break since 2012. The majority of MDR-AB outbreaks were
found in our hospital, and there was no transfer to other hos-
pitals in the same medical area. On average, 51 cases of
Acinetobacter spp., including A. baumannii, colonization
were detected yearly from 2003 to 2011 prior to the out-
break. However, the number of Acinetobacter spp. cases
increased to 115 in 2012, 80 in 2013, 97 in 2014, and 100 in
2015. Since 2012, signiﬁcant efforts, included clariﬁcation
of the clinical features between antibiograms and
polymerase chain reaction (PCR) patterns of A. baumannii
isolates. The present study investigated the relationship
between A. baumannii genotypes and their resistance to
antibiotics.
METHODS
Study design, setting, and participants
THIS STUDY WAS carried out at Juntendo UniversityUrayasu Hospital, a 653-bed facility that includes 15
and in the CCC. The CCC serves approximately 1.6 million
people residing in the east side of Chiba prefecture, which is
located adjacent to Tokyo, Japan. Approximately 22,000
patients, including approximately 5000 patients in critical
condition transported by ambulance, are treated in the emer-
gency center annually. These include trauma, burn, poison-
ing, cardiopulmonary arrest, shock, and other critical
internal medical conditions.
We screened a sputum or throat swab, using selective
medium for isolation of Acinetobacter spp., at the time of
admission to the CCC and weekly thereafter as a surveil-
lance. Bacterial cultures obtained from the surveillance
undertaken in the CCC between January 2012 and Septem-
ber 2015 included A. baumannii. Exclusion criteria were
death within 24 h of admission, and pediatric patients
<15 years old.
Definitions of MDR-AB and extensively drug-
resistant A. baumannii
According to the new deﬁnition for drug-resistant A. bau-
mannii provided by the European Centre for Disease
Prevention and Control and the Centers for Disease Control
and Prevention, MDR-AB is deﬁned as A. baumannii with
non-susceptibility to one or more agents in at least three or
more of the following categories: combinations of peni-
cillins and b-lactam inhibitors, extended-spectrum cephalos-
porins, aminoglycosides, ﬂuoroquinolones, carbapenems,
polymyxins, and tigecycline. Extensively drug-resistant
A. baumannii (XDR-AB) is deﬁned as non-susceptibility to
one or more agents in the standard categories except
polymyxins or tigecycline.7
Antimicrobial susceptibility testing
Once bacteria were cultured from the sputum or throat swab
sample, antimicrobial susceptibility tests for common bacte-
ria were undertaken to identify the causative agent according
to the routine protocol of our bacteriology laboratory. Mini-
mal inhibitory concentrations against piperacillin (PIPC),
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ceftazidime (CAZ), meropenem (MEPM), levoﬂoxacin
(LVFX), and amikacin (AMK) were determined using the
broth microdilution method according to guidelines from the
Clinical and Laboratory Standards Institute.8
Amplification of carbapenem resistance
genes and IS by PCR
For samples with successful A. baumannii culture and isola-
tion, the presence of carbapenemase genes (OXA-23-like,
OXA-24-like, OXA-51-like, and OXA-58-like) were evalu-
ated by multiplex PCR using four pairs of previously
described primers9,10 using the LightCycler 96 system
(Roche, Tokyo, Japan). Additionally, two MBL genes
(IMP- and VIM-like) were also evaluated by PCR as previ-
ously described.11 The presence of ISAba1 element in all
A. baumannii isolates was assessed by PCR, using the HFR
and HRR primers12 and the LightCycler 96 system.
Pulsed-field gel electrophoresis and
multilocus sequence typing
The genetic relationship of all A. baumannii isolate was
determined by pulsed-ﬁeld gel electrophoresis (PFGE)
using the Sma1 restriction enzyme (Takara Bio, Kusatsu,
Japan). Pulsed-ﬁeld gel electrophoresis was carried out
using a Fingerprinting II software version 3.0 with sup-
port from SRL (Japan). Relatedness determinations were
carried out as previously described.13 Sequence types
(STs) for A. baumannii were determined by multilocus
sequence typing (MLST), speciﬁcally for clonal lineages
using the Pasteur scheme,14,15 by ampliﬁcation and
sequence analysis of fragments of seven internal
housekeeping genes (cpn60, fusA, gltA, pyrG, recA,
rplB, and rpoB). Determination of the STs was carried
out using the Pasteur MLST database website (http://
pubmlst.org/abaumannii/).
RESULTS
Patient background and bacteria isolation
THE ENROLLMENT CRITERIA for the study are pro-vided in Figure 1. During the observation period, 1634
patients were admitted to the CCC. Of these, 281 patients
had positive cultures from sputum or throat swab. Nine
patients were excluded: ﬁve were pediatric patients
(<15 years old), and four patients died within 24 h of admis-
sion. After the exclusion, samples from 272 patients were
further studied.
Acinetobacter baumannii was detected in 43 patients with
an average age of 58  19 years. The majority of patients
were men (29/43, 67.4%). Three patients were identiﬁed as
having acquired nosocomial infection: two patients were
diagnosed with ventilator associated pneumonia due to
A. baumannii, and one patient was positive for A. bauman-
nii from blood cultures. Forty patients were colonized with
A. baumannii.
Genotypic determination and antimicrobial
susceptibility testing
The carbapenemase genotypes of A. baumannii are listed in
Table 1. Multiplex PCR identiﬁed the same A. baumannii
genotype (possessing OXA-51-like, ISAba1, and IMP, but
not OXA-23-like, OXA-40-like, OXA-58-like, or VIM) in
Fig. 1. Summary of study design and
participants. After implementing the
exclusion criteria, Acinetobacter bau-
mannii was detected in 43 patients
treated in the critical care center (CCC)
at Juntendo University Urayasu Hospi-
tal (Urayasu, Japan) between January
2012 and September 2015.
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six of the 43 patients. The average age of patients with this
genotype of A. baumannii was 51  24 years, and 33.3%
(2/6) were men. Their average length of stay in the CCC
was 26  5 days (Table 2). Acinetobacter baumannii iso-
lated from these patients were resistant to PIPC, CAZ,
MEPM, LVFX, and AMK (Fig. 2A). These isolates were
determined to be XDR-AB.
Acinetobacter baumannii from 21 of the 43 patients had
OXA-51-like and ISAba1, but not IMP, OXA-23-like,
OXA-40-like, OXA-58-like, or VIM. The average age of
these patients was 53  16 years, and 76.2% (16/21) were
male. Their average length of stay at the CCC was
25  13 days (Table 2). These isolates were not susceptible
to PIPC, CAZ, LVFX, or AMK, and were susceptible to
MEPM (Fig. 2B). They were determined to be MDR-AB.
The other 16 patients had A. baumannii possessing only
the OXA-51-like genotype, and not ISAba1, OXA-23-like,
OXA-40-like, OXA-58-like, IMP, or VIM. The average age
of these patients was 68  13 years and 68.7% (11/16)
were men. Their average CCC stay was 14  10 days
(Table 2). These isolates were sensitive to virtually all
drugs: PIPC (6.3%), CAZ (0%), MEPM (0%), LVFX
(6.3%), and AMK (6.3%) (Fig. 2C).
Based on these results, the antibiotic susceptibility or
resistance was signiﬁcantly associated with certain A. bau-
mannii genotypes. Therefore, antimicrobial susceptibility
could indicate the genotype of A. baumannii.
Pulsed field gel electrophoresis and MLST
findings
Pulsed ﬁeld gel electrophoresis was undertaken for samples
from all 43 patients with A. baumannii including those with
XDR-AB and MDR-AB. Isolates from three patients (nos.
10, 33, and 40) were excluded due to the potential for con-
tamination with other bacteria during long-term sample stor-
age at 80°C. The PFGE results showed that isolates from
26 patients with A. baumannii genotypes carrying OXA-51-
like and ISAba1, regardless of the presence of the IMP gene,
belonged to two closely related types: PFGE type X-1 and
X-2 (Fig. 3). The similarity coefﬁcient for isolates from
these two PFGE types was 93%. Based on this similarity,
Table 1. Genotypic determination of carbapenemase genes of Acinetobacter baumannii
Patient no. Carbapenemase genotype
OXA-23 OXA-40 OXA-51 OXA-58 ISAba1 IMP VIM
25, 34, 36, 37, 38, 39   +  + + 
1, 3, 4, 5, 6, 8, 10, 11, 12, 13, 14, 15, 22, 23, 24, 26, 29, 30, 31, 35, 41   +  +  
2, 7, 9, 16, 17, 18, 19, 20, 21, 27, 28, 32, 33, 40, 42, 43   +    
Table 2. Patient background and Acinetobacter baumannii genotypes
Genotype OXA-51-like(+)
ISA-ba1(+)
IMP(+)
OXA-51-like(+)
ISA-ba1(+)
IMP()
OXA-51-like(+)
ISA-ba1()
IMP()
Number of patients 6 21 16
Age (years) 51  24 53  16 68  13
Sex (% male) 33.3 76.2 68.7
Time in CCC (days) 26  5 25  13 14  10
Drug resistance Resistant to PIPC, CAZ,
MEPM, LVFX, and AMK (XDR-AB)
Not susceptible to PIPC, CAZ,
LVFX or AMK; susceptible
to MEPM (MDR-AB)
Sensitive to virtually all drugs:
PIPC (6.3%), CAZ (0%), MEPM (0%),
LVFX (6.3%), and AMK (6.3%)
PFGE type X-1 X-1 or X-2 Y1-14
Spreading in CCC Yes Yes No
AMK, amikacin; CAZ, ceftazidime; CCC, critical care center; LVFX, levofloxacin; MDR-AB, multidrug-resistant A. baumannii; MEPM, merope-
nem; PFGE, pulsed-field gel electrophoresis; PIPC, piperacillin; XDR-AB, extensively drug-resistant A. baumannii.
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we hypothesized that closely related A. baumannii geno-
types had been spreading in the CCC for 4 years.
In contrast, A. baumannii isolated from the other 14
patients (OXA-51-like(+) ISAba1() IMP() genotype)
were detected as various clones belonging to PFGE type Y-
1 to Y-14 (Fig. 3). The lineage clonality of these A. bau-
mannii isolates was low, and the similarity coefﬁcient was
approximately 55–75%.
Results of the MLST showed that the PFGE type X-1 and
X-2 isolates carrying OXA-51-like and ISAba1 belonged to
ST2 according to the protocol of the Pasteur Institute (two
alleles each for cpn60, fusA, gltA, pyrG, recA, rplB, and
rpoB). Those belonging to GCII were the only strains that
could cause outbreaks in our CCC and potentially could
have spread from the CCC throughout the hospital.
DISCUSSION
TO DATE, MOST of the previous studies about MDR-AB were international spread or multicenter studies,
because MDR-AB is rarely detected.2 The present study
shows the relationship of A. baumannii from 43 patients in
terms of the susceptibility, genotype, and molecular type at
a single center. This study shows that genotypic determina-
tion of A. baumannii can predict the susceptibility to
antimicrobial drugs. We found that two closely related
strains, as determined by molecular characterization by
PFGE and MLST, had spread in our CCC. Therefore, we
could predict whether the genotype spread in the CCC or
not when the susceptibility was examined, facilitating the
appropriate isolation of patients. This isolation method can
be applied not only to A. baumannii but also to Gram-nega-
tive bacillus when susceptibility is consistent with the geno-
type of bacteria.
Speciﬁcally, A. baumannii genotypes carrying OXA-51-
like and ISAba1 had spread in our CCC. Four OXA
enzymes of A. baumannii have been reported to cause out-
breaks globally, with OXA-23-like and OXA-51-like as the
major oxacillinases associated with outbreaks in Asia.2 The
strains isolated in our CCC also carried OXA-51-like; how-
ever, they did not possess the OXA-23-like gene. Based on
the MLST results, the strains found to be spreading in the
CCC belonged to GCII, which has been associated with the
presence of OXA-51 and ISAba1, OXA-23, OXA-40, or
OXA-58.3 In our CCC, the GCII strains possessed OXA-51-
like and ISAba1.
To date, the IMP gene has been identiﬁed in A. bauman-
nii in a variety of geographic regions, including Italy, Spain,
Portugal, Greece, Australia, Japan, Singapore, Korea, and
Hong Kong.2,6,16 The present PCR and PFGE analyses
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Fig. 2. Antimicrobial susceptibility of Acinetobacter baumannii according to genotype. Susceptibility to piperacillin (PIPC), cef-
tazidime (CAZ), meropenem (MEPM), levofloxacin (LVFX), and amikacin (AMK) was evaluated according to Clinical and Laboratory Stan-
dards Institute guidelines. A, Antimicrobial susceptibility of the OXA-51-like(+) ISAba1(+) IMP(+) genotype. B, Antimicrobial
susceptibility of the OXA-51-like(+) ISAba1(+) IMP() genotype. C, Antimicrobial susceptibility of the OXA-51-like(+) ISAba1() IMP()
genotype. White bars, sensitive (S); gray bars, intermediate-sensitive (I); black bars, resistant (R).
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revealed that six patients harbored A. baumannii with the
IMP gene and the PFGE type X-1 detected two genotype
strains: IMP(+) and IMP(). Plasmids carrying the IMP
gene were more than 60 kbp.17 The PFGE analysis we used
was capable of detecting differences of approximately 50–
300 kbp. However, plasmids containing the IMP gene could
not be detected by PFGE, and both the IMP(+) and IMP()
genotypes would be assigned to the same molecular type.
Some limitations exist in this study. First, the present out-
break of A. baumannii is characterized by the speciﬁc geno-
type, OXA-51-like(+) and ISAba1(+), in the CCC.
However, other molecularly characterized strains could be
spread in other hospitals and must be detected independently
by PCR and PFGE. Second, A. baumannii can easily
acquire multidrug resistance owing to plasmid-mediated
gene transformation.5 However, as has been stated, the
PFGE type X-1 belonged to OXA-51-like(+) and ISAba1(+)
regardless of the presence of the IMP gene, and the PFGE
technique was unable to detect minor genetic differences,
such as the IMP gene.
In conclusion, susceptibility to antimicrobial drugs can
predict A. baumannii genotypic types in the CCC.
Fig. 3. Results of pulsed-field gel elec-
trophoresis (PFGE) analysis of Acineto-
bacter baumannii carrying OXA-51-like
and ISAba1 from 26 patients, which
belong to two closely related PFGE
types, X-1 and X-2.
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